26 patents currently held
26 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Jul 2027. from the record
Of the 26 now held by other companies, 21 name Amgen Inc. as their current owner, and 5 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Jul 2027
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2028 · High confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends Apr 2031 · High confidence
Also notable
Ends Feb 2037 · High confidence
Also notable
Ends Feb 2037 · High confidence
Also notable
Ends Feb 2037 · High confidence
Also notable
Ends Sep 2027 · High confidence
Also notable
Ends no later than May 2034 · Medium confidence
Composition Comprising Cross-Species-Sepecific Antibodies and Uses Thereof
US 8,236,308
The most cited patent in this portfolio, cited by 326 later US patents, top 1% of utility patents granted in 2012 in our data. Protection runs to 2028.
Antibody Constructs for DLL3 and CD3
US 10,294,300
Cited by 68 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens
US 9,260,522
Cited by 113 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Bispecific T Cell Engaging Antibody Constructs
US 11,434,302
Cited by 33 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2037.
Antibody Constructs for FLT3 and CD3
US 11,447,567
Cited by 38 later US patents, top 5% of utility patents granted in 2022 in our data. Protection runs to 2037.
PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs
US 10,781,264
Cited by 25 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2037.
Means and Methods for the Treatment of Tumorous Diseases
US 8,007,796
Cited by 34 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Antibody Constructs for CDH19 and CD3
US 11,498,964
Granted 2022. Computed term ends 2034. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Formerly held, still cited
Notable
Ends Nov 2032 · High confidence
Cited by 18 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2032. A terminal disclaimer caps this term to an earlier patent's.
now held by Amgen Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 24, 2027The maintenance fee for Means and Methods for Treating Dlbcl (US 9,192,665) comes due May 24, 2027. Unpaid by Nov 24, 2027, it lapses early.
- 1 fee due Aug 16, 2027The maintenance fee for Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens (US 9,260,522) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
- 1 fee due Sep 12, 2027The maintenance fee for Compositions Comprising Cross-Species-Specific Antibodies and Uses Thereof (US 11,925,684) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
- 4 of the patents on this record were granted since Aug 22, 2026
What they patent
The largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,154,617 | Means and Methods for the Treament of B Cell Non-Hodgkin Lymphoma and B Cell Leukemia In force · Medium confidence | In force | Medium confidence | |
| US 8,007,796 | Means and Methods for the Treatment of Tumorous Diseases In force · High confidence | In force | High confidence | |
| US 8,236,308 | Composition Comprising Cross-Species-Sepecific Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,925,684 | Compositions Comprising Cross-Species-Specific Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,047,159 | Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens In force · High confidence | In force | High confidence | |
| US 9,260,522 | Bispecific Single Chain Antibodies with Specificity for High Molecular Weight Target Antigens In force · High confidence | In force | High confidence | |
| US 10,696,744 | Means and Methods for Treating Dlbcl In force · Medium confidence | In force | Medium confidence | |
| US 11,633,408 | Prevention of Adverse Effects Caused by CD3 Specific Binding Domains In force · Low confidence | In force | Low confidence | |
| US 9,192,665 | Means and Methods for Treating Dlbcl In force · High confidence | In force | High confidence | |
| US 11,579,142 | Dosage Regimen for Administering a CD19XCD3 Bispecific Antibody to Patients at Risk for Potential Adverse Effects In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 26: 26 patents in force now held by others · 2 patents ended · 42 applications pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.